Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | DRD4 | P21917 | 3/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.56 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13311736 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2SIGMAR1MAPTMAPK1DRD4 | |
| SCHEMBL2326970 | 0.79 | TFPI2 (0.68) | KMT2ATFPI2 | |
| SCHEMBL9880151 | 0.79 | TFPI2 (0.68) | KMT2ATFPI2 | |
| SCHEMBL19341777 | 0.79 | TFPI2 (0.68) | KMT2ATFPI2 | |
| SCHEMBL2425554 | 0.78 | SIGMAR1 (0.78) | SIGMAR1MAPK1DRD4DRD2DRD3 | |
| SCHEMBL2333833 | 0.76 | PPP1CA (0.49) | SIGMAR1TFPI2LMNAPPP1CA | |
| Hydrochloric Acid SCHEMBL21410212 | 0.76 | SIGMAR1 (0.76) | SIGMAR1MAPK1DRD4DRD2DRD3 | |
| SCHEMBL6378224 | 0.76 | CYP2C19 (0.70) | SMN1; SMN2SIGMAR1DRD4DRD2DRD3 | |
| SCHEMBL3164487 | 0.75 | SIGMAR1 (0.74) | SIGMAR1MAPK1DRD4DRD2DRD3 | |
| SCHEMBL28996046 | 0.75 | SIGMAR1 (0.74) | SIGMAR1MAPK1DRD4DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137294-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | GENETIC TECHNOLOGIES LIMITED (AU) | 2010-06-03 | — | — | US | disclosed |
| EP-2086534-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | Genetic Technologies Limited (AU) | 2009-08-12 | — | — | EP | disclosed |
| WO-2008058342-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | GENETIC TECHNOLOGIES LIMITED (AU) | 2008-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137294-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR CONTROLLING INVERTEBRATE PESTS | PPP1R10, TASP1, PPP5C | SMN1; SMN2 3065/4885SIGMAR1 4693/4885MAPT 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.